Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2025 07:00 ET | Source: AC Immune SA

AC Immune to Present at the Jefferies 2025 London Healthcare Conference

AC Immune to Present at the Jefferies 2025 London Healthcare Conference Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
November 11, 2025 07:00 ET | Source: Neuphoria Therapeutics, Inc.

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE...
November 11, 2025 07:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement

REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare...
November 11, 2025 02:00 ET | Source: Ariceum Therapeutics

Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma

225Ac-SSO110 has received U.S. FDA Orphan Drug Designation Initial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026 Potential to address a broad range of neuroendocrine cancers ...
November 10, 2025 21:56 ET | Source: Vor Biopharma

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the...
November 10, 2025 17:30 ET | Source: Rezolute, Inc.

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by...
November 10, 2025 16:15 ET | Source: ProKidney

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the...
November 10, 2025 16:09 ET | Source: LAVA Therapeutics N.V.

LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to LAVA shareholders related to the proposed...
November 10, 2025 16:05 ET | Source: Insight Molecular Diagnostics Inc.

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay’s...
November 10, 2025 16:05 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call...